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Abstract
Background: HIV replication in mononuclear phagocytes is a multi-step process regulated by viral and cellular proteins with
the peculiar feature of virion budding and accumulation in intra-cytoplasmic vesicles. Interaction of urokinase-type
plasminogen activator (uPA) with its cell surface receptor (uPAR) has been shown to favor virion accumulation in such sub-
cellular compartment in primary monocyte-derived macrophages and chronically infected promonocytic U1 cells
differentiated into macrophage-like cells by stimulation with phorbol myristate acetate (PMA). By adopting this latter model
system, we have here investigated which intracellular signaling pathways were triggered by uPA/uPAR interaction leading
the redirection of virion accumulation in intra-cytoplasmic vesicles.
Results: uPA induced activation of RhoA, PKCd and PKCe in PMA-differentiated U1 cells. In the same conditions, RhoA, PKCd
and PKCe modulated uPA-induced cell adhesion and polarization, whereas only RhoA and PKCe were also responsible for
the redirection of virions in intracellular vesicles. Distribution of G and F actin revealed that uPA reorganized the
cytoskeleton in both adherent and polarized cells. The role of G and F actin isoforms was unveiled by the use of cytochalasin
D, a cell-permeable fungal toxin that prevents F actin polymerization. Receptor-independent cytoskeleton remodeling by
Cytochalasin D resulted in cell adhesion, polarization and intracellular accumulation of HIV virions similar to the effects
gained with uPA.
Conclusions: These findings illustrate the potential contribution of the uPA/uPAR system in the generation and/or
maintenance of intra-cytoplasmic vesicles that actively accumulate virions, thus sustaining the presence of HIV reservoirs of
macrophage origin. In addition, our observations also provide evidences that pathways controlling cytoskeleton remodeling
and activation of PKCe bear relevance for the design of new antiviral strategies aimed at interfering with the partitioning of
virion budding between intra-cytoplasmic vesicles and plasma membrane in infected human macrophages.
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Introduction
Urokinase-type plasminogen activator (uPA) is a serine protease
that activates plasminogen to plasmin [1] and is synthesized as an
inactive precursor (pro-uPA) that undergoes proteolytic activation.
Both pro-uPA and uPA bind to a specific glycosyl-phospatidyl-
inositol (GPI)-anchored receptor, uPAR, on the cell surface [2]
and are expressed by inflammatory cells including neutrophils,
mononuclear phagocytes (MP), and activated T lymphocytes [2]
for which cells they play important roles in cell activation,
adhesion and migration. In addition to focusing the proteolytic
activity of uPA on the surface of the cells, extracellular uPAR acts
as a functional receptor of uPA-dependent signaling [3], inducing
cell adhesion, migration, and proliferation in different cell types
independently of its catalytic component [4,5].
Of particular relevance is the fact that the uPA system seems to
represent an overlapping mechanism involved in both tumor and
HIV disease progression [6]. The full-length soluble form of uPAR
(suPAR) is predictive of negative clinical outcome in different
diseases including cancer [7] and HIV/AIDS. In this latter
condition, suPAR represents a novel prognostic indicator which
was shown to be independent from and as indicative as low
numbers of circulating CD4
+ T cells or high viremia levels [8].
Furthermore, suPAR correlated with the state of immune
activation of HIV-infected individuals, as well as with the lipid
and glucose metabolism [9]. Of note, higher levels of suPAR were
demonstrated not only in the plasma/serum of HIV
+ individuals
[10,11], but also in the central spinal fluid (CSF) of neurologically
compromised HIV
+ individuals [12,13] and correlated with CSF
viral load [13]. Since we have previously reported that uPA
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inducing their accumulation into intracellular vesicles [14],
independently of its enzymatic activity but through binding to
uPAR followed by vitronectin dependent adhesion [15] these
observations suggest that the increased levels of suPAR may work
as a soluble receptor complexing and preventing uPA from
exerting an anti-HIV activity in vivo.
Since uPAR is GPI-anchored receptor with no intracellular
domain it requires the interaction with signaling-competent
transmembrane proteins for triggering signal transduction [16].
To date, the most well characterized uPAR partners include
integrins [3], the G-protein coupled receptor formyl peptide
receptor ligand 1 (FPRL1) [3], and gp130, the signal transducing
subunit of the IL-6 R family [17]. uPAR and integrins act as a
single functional unit in several cells. Of interest is the fact that
monocytes from uPAR-deficient mice fail to adhere onto
fibrinogen and to migrate upon thioglycollate stimulation [18] in
spite of the expression of the signaling-competent integrin CD11b-
CD18 (Mac-1). In this regard, we have recently reported that uPA
increased the adhesion to the substrate of both primary human
monocyte-derived macrophages (MDM) and of chronically
infected promonocytic U1 cells differentiated to macrophage-like
cells by phorbol myristate acetate (PMA). Adhesion to the
substrate was responsible for uPA-mediated inhibition of HIV
expression in these infected cells and was mediated by vitronectin
(VN) binding to the uPA/uPAR complex [15]. The ability of the
uPA/uPAR/VN complex to redirect virions into intra-cytoplasmic
vesicles was independent of the catalytic activity of uPA but was
induced by the amino-terminal fragment (ATF) of uPA, competent
for intracellular signaling [14,15,19,20]. The general mechanism
of uPA-mediated inhibition of HIV replication in macrophages is
related to the induction of an increased accumulation of virions
budding into intra-cytoplasmic vacuolar compartments of debated
nature, a peculiar feature of infected MP not observed in CD4
+ T
lymphocytes [21]. This morphological feature of MP has suggested
the model of infected macrophages as ‘‘Trojan horses’’ of HIV
infection contributing to the generation/maintenance of viral
reservoirs in anatomical sites such as the CNS [22]. In addition to
other stimuli, including interferon-c (IFN-c) [23], CCL2 [24], and
Mac-1 ligands [14], the uPA/uPAR/VN system might thus
represent a mechanism leading to intracellular entrapment of
virions into the vesicles.
In this study, we have investigated the nature of the intracellular
signaling triggered by uPA/uPAR interaction responsible for the
intracellular accumulation of HIV virions. In particular, we have
focused our attention on the small GTPase RhoA and PKC
isoforms, previously reported to mediate cell motility, chemotaxis,
adhesion, migration and stress fiber formation [25], activities that
can be mediated by uPA/uPAR interaction independently of
uPA catalytic activity [4,5]. In this regard, we have previously
demonstrated that uPA induces similar HIV virion morphogenetic
features in PMA-differentiated adherent U1 cells [19,26] and in
primary MDM either infected in vitro [19] or differentiated ex-vivo
from monocytes of infected individuals [15]. The present study has
been performed in the convenient model of PMA-differentiated
U1 cells permitting a broader range of experimental conditions
than primary MDM obtained from different donors.
Materials and Methods
Reagents
LPS-free (bacterial endotoxin ,2610
25 EU/IU corresponding
to ,10
210 EU/mg) human uPA (M.W. of 52 kDa) was provided
by Dr. Jack Henkin (Abbot Laboratories, IL, USA) and Andrew P.
Mazar (Chemistry of Life Processes Institute, Evanston, IL), and
was used at 10 nM based on our previous studies [14]. This
concentration reflects uPA binding affinity for uPAR (0.1–1 nM)
[27] and its levels determined in pathological conditions [28],
including serum levels in HIV-1
+ individuals [29]. Hoechst-33342,
DNase I Alexa Fluor 488, phalloidin Alexa Fluor 633 were from
Molecular Probes (Eugene, OR). Triton X-100, crystal violet,
rabbit anti-goat FITC antibodies (Ab) and phorbol-12, myristate-
13, acetate (PMA) were purchased from Sigma Chemical Corp.
(St. Louis, MO), monoclonal Ab (mAb) against different PKC
isoforms were obtained from BD Transduction Laboratories (B-
9320 Erembodegem, Belgium), and polyclonal Ab against the
phosphorylated form of PKCe and PKCd from Santa Cruz
Biotechnology (Santa Cruz, CA). PMA was resuspended in
ethanol at 1 mM and used at 10 nM. Cytochalasin D was from
Calbiochem (Merck KGaA, Darmstadt, Germany) and was
resuspended in DMSO and used at 10 mM, based on preliminary
experiments identifying non-toxic concentrations for U1 cells,
defined as [
3H]-thymidine uptake and vital cell counts after
Trypan blue staining. Penetratin-1 (P1) and P1 fusion peptide
containing RhoA/23–40 (P1/23–40), RhoA/92–119 (P1/92–119)
and PKC myristoylated pseudosubstrate peptides were dissolved in
DMSO at 10 mM and were used at the final concentration of
50 mM [30]. Paraformaldehyde (PFA) was purchased from Merck.
Round coverslips were from Zeus (Zeus Scientific, Branchburg,
NJ), whereas microscope glass slides were obtained from BDH
(Poole, UK). Mowiol 4–88 was bought from Calbiochem.
Experiments were performed in either standard tissue culture
plates (Falcon, BD Biosciences, Bedford, MA) or in Teflon-coated
ultra-low adhesion (ULA) plates to rule in/out the contribution of
cell adhesion to the investigated hypothesis.
Chronically HIV-infected U1 cell line
The promonocytic U1 cell line was originally obtained from a
population of U937 cells surviving the cytopathic effect of acute
CXCR4-dependent HIV-1LAI/IIIB infection; each U1 cell contains
2 copies of integrated proviruses [26]. No virus production is
detected by conventional reverse transcriptase (RT) activity assay
or p24 Gag antigen ELISA in cultures of unstimulated U1 cells,
but virus expression at levels comparable to those achieved at peak
of acute virus infection of parental U937 cells or primary MDM
and T cell blasts is rapidly induced by stimulation of U1 cells with
PMA or pro-inflammatory cytokines [26]. U1 cells (2610
5 cells/
ml, unless otherwise indicated, in RPMI 1640 containing 10% of
heat-inactivated FCS, 1% pen/strep and 1% glutammine) were
incubated with uPA (10 nM), PMA (10 nM) or PMA+uPA in the
presence or absence of the above mentioned peptides and
reagents. All experiments were performed with U1 cells kept in
culture medium containing 10% of FCS because serum starvation
(observed at FCS concentrations ,2%) prevents uPA-induced
adhesion and inhibition of HIV expression, likely consequent to
the reduced amounts of VN in the culture medium [15]. Thus, we
decide to keep the 10% of serum in our culture medium in order
to allow the proper formation of the uPA/uPAR/VN system, and
likely the generation of unbiased intracellular signal(s).
Supernatant- vs. cell-associated virus
HIV-1 virion release in culture supernatants was monitored by
determination of Mg
++-dependent RT activity. Since 99% of the
RT enzyme is virion-associated, this assay is a faithful indication of
the production of new progeny virions [31]. In order to quantify
the levels of cell-associated RT activity, cells were washed twice
with culture medium at room temperature and subjected to 5
consecutive cycles of cell freezing and thawing [14].
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Cell proliferation and adhesion were measured after 48 h of
stimulation in triplicate cultures in 96 flat-bottomed well tissue
culture plates, as reported [14,15].
Optical microscopy
Pictures of cell cultures in the different experimental conditions
were acquired with an optical phase contrast Leica DM IL
microscope and analyzed by FireCam software (Leica, Deerfield,
IL). Pictures of suspended cells or cell clustering were directly
taken in the original culture well. Pictures of adherent cells were
taken after removal of culture supernatants (i.e., including floating
cells, such as present in PMA-stimulated U1 cells, representing
about 60% of cells and segregated into the clusters), 2 washes with
warm culture medium, 1 wash with 4% PFA in PBS, and 20 min
fixation in PFA/PBS at room temperature.
Quantification of polarized cells
U1 cells were washed and resuspended in culture medium
without serum at concentration of 5610
5 cells/ml, and incubated
with Cell Tracker Red CMPTX (1 mM, Invitrogen) for 30 min at
37uC,5%CO2.Cellswerethenwashedand resuspendedat25610
3
cells/ml in standard medium supplemented of 10% FCS and left
untreated or incubated with RhoA and PKCs inhibitors for 45 min
at 37uC, 5% CO2 before stimulation with PMA in the presence or
absence of uPA. After 48 h cells were washed with warm PBS and
adherent cells were fixed with warm 2% PFA/PBS for 15 min at
room temperature. Intracellular actin was then stained with
phalloidin-FITC (8 mM, Sigma) in 1 ml of saponin buffer (0.1%
saponin and 0.5% BSA in PBS) for 30 min at room temperature.
Cells were then washed twice with warm PBS and stained with
Hoechst 33342 trihydrochloride trihydrate (Invitrogen) at the
concentration of 3.24 mM in PBS for 15 min at room temperature.
Cells were washed twice with PBS and maintained in PBS.
Approximately 250 random fields were automatically acquired by
the IN Cell Analyzer 1000 (GE Healthcare, Fairfield, CT), using
objectivemagnification of406.Analysiswas performedwith InCell
Investigator Software: polarized cells were identified using the
‘‘form factor’’, a standard estimate of circularity that relates
perimeter length to area. This measurement varies from 0 to 1,
with 1 being a perfect circle. A threshold of 0.8 was fixed for this
parameter and cells with a ‘‘form factor’’ lower than threshold
classified as polarized cells. Cell polarization was based on the form
factor as automatically calculated by the IN Cell Investigator
Software (GE Healthcare); ratio below 0.8 was used to identify
polarized cells, because was identified as the threshold discriminat-
ing between round and stretched cell shapes. Picture montage was
performed by using the ImageJ software.
Intracellular distribution of filamentous and globular
actin
U1 cells were stimulated with the reported stimuli and plated on
top of round coverslip. Two days later coverslips were washed twice
with PBS and adherent cells fixed with 4% buffered PFA for
20 minutes at room temperature, washed twice with PBS cells and
permeabilized by 0.1% Tryton X-100 in PBS for 5 min at room
temperature. After two more washes with PBS cells were stained
with Hoechst-33342 (3.24 mM in PBS), DNase I Alexa Fluor 488
(0.3 mM in PBS) and phalloidin Alexa Fluor 633 (0.165 mMi nP B S )
for 20 min at room temperature. After two more washes with
PBS cells were mounted and sealed on microscope glass slide with
Mowiol 4–88. Images were acquired by Leica TCS SP2 con-
focal microscope (Leica Microsystems CMS GmbH, Mannheim,
Germany) using objective magnification 636. Picture montage was
performed by using the ImageJ software.
Ultrastructural study
U1 cells were stimulated with PMA in the presence or absence
of uPA and aliquots of 5610
6 cells were then washed in Phosphate
Buffered Saline (PBS) and analyzed after 48 h by electron
microscopy as previously described [14]. Briefly, U1 cells were
washed twice in PBS, fixed in 4% (vol/vol) glutaraldehyde/2%
(wt/vol) PFA/cachodilate (0.12 M pH: 7.4) and postfixed in 1%
(vol/vol) OsO4 (0.12 M) cachodilate buffer. Cells were dehydrated
in graded ethanol, washed in propylene oxide and infiltrated for
12 h in a 1:1 mixture of propylene oxyde:epoxydic resin (Epon).
Cells then were embedded in Epon and polymerized for 24 h at
60uC. Slides were cut with ultramicrotome (Ultracut Uct, Leica),
stained with uranyl acetate and lead citrate, and metallized.
Protein kinase C (PKC) translocation and activation
U1 cells were washed and aliquots of 5610
6 cells were
resuspended in 12.5 ml of RPMI 10% FCS and either left
unstimulated or were stimulated with PMA in the presence or
absence of uPA at the indicated time points. U1 cells were then
centrifuged at 1,200 rpm for 10 min at 4uC, the culture medium
was removed and the cells were resuspended in 300 ml of cold
homogenization buffer [Hepes/K (20 mM pH:7.6), EDTA/K
(5 mM pH:8), EGTA/K (5 mM pH:7.6), DTT (5 mM), Na3VO4
(1 mM), NaF (2 mM)] and protease inhibitor cocktail (1:1,000 vol/
vol; Sigma). Cells were homogenized by 5 consecutive passages
trough a 22G needle mounted onto a 1 ml syringe. The cell
homogenates (250 ml) were transferred into ultracentrifuge tubes
(Beckman Coulter, Fullerton, CA) and spun at 100,000 g for
60 min at 4uC (at 50,000 rpm in ultra TL-100 with the TLA-100.3
rotor or at 42,000 rpm with the TLA-55 rotor, Beckman). The
supernatants containing cytosolic proteins were then collected,
whereas the pellets were resuspended in 120 ml of the homogeni-
zation buffer supplemented of 1% TritonX-100, centrifuged at
100,000 g for 30 min at 4uC (Beckman) and the supernatants
containing membrane proteins were collected. Finally, 10 mgo f
either cytosolic or membrane-associated proteins were loaded on
10% SDS-PAGE and analyzed by Western blotting using mAb
directed against specific PKC isoforms a, d, e.
Cytofluorimetric analysis of phoshorylated PKCe and PKCd was
performed on cells that were washed with cold PBS, fixed with 2%
PFA/PBS for 15 min at room temperature, permeabilized with
saponin buffer in the presence of the specific Ab for 30 min at room
temperature, followed by one wash with saponin buffer and further
30 min of incubation with the secondary anti-goat FITC Ab. An
averageof15,000cellsperconditionwasacquiredusinga FACScan
(Becton Dickinson, Franklin Lakes, NJ) flow cytometry apparatus
and analyzed by the CellQuest software (Becton Dickinson).
Determination of RhoA activation
The amount of the active form of RhoA (GTP-bound RhoA)
was assessed using the G-LISA RhoA Activation Assay Kit
(Absorbance Based; Cytoskeleton, Inc., Denver, CO) according to
the manufacturer’s protocol. Cell (5610
6) were washed and
resuspended in culture medium (1 ml) in the presence or absence
of stimuli for the indicated time points and 10 mg of protein were
used for the assay.
Statistics
Each experiment was design to analyze cell adhesion, clustering
andpolarizationaswellasHIVexpressioninthesame experimental
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The results are reported as mean 6 standard deviation (SD).
Multivariate analyses were conducted by one-way ANOVA and by
the Tukey post-test. Differences were considered significant if
p,0.05.
Results
The intracellular accumulation of virions induced by uPA
in PMA-differentiated U1 cells is mediated by activation
of small GTPase RhoA and PKCe, but not PKCd
We have previously reported that the cell adhesion–dependent
antiviral signal triggered by uPA binding to uPAR requires b1 and
b2 integrin chains [14]. We therefore investigated whether the
small GTPase RhoA was mediating the intracellular accumulation
of HIV virions observed upon uPA treatment of U1 cells
stimulated with PMA since RhoA is known to influence cell
adhesion by promoting integrin activation [32]. HIV expression
from U1 cells was induced by PMA stimulation (Figure 1A and
1B), while uPA inhibited more than 50% of virus expression by
promoting virion accumulation in intracellular vesicles (Figure 1C),
as previously reported [14,20].
The Trojan peptides P1/23–40 and P1/92–119 were previously
shown to specifically target the small GTPase RhoA [30] thus
inhibiting the transition from low to intermediate and to high
affinity state and/or the lateral mobility of the b2 integrin
leukocyte functional antigen-1 (LFA-1, also known as CD11a/
CD18), respectively. RhoA trojan peptides did not influence HIV
expression in unstimulated U1 cells (data not shown) or in cells
stimulated only with PMA, while they abrogated the anti-HIV
activity of uPA (Figure 1A). Penetratin1 (P1), the common
fusogenic component of Trojan peptides, was used as control [30].
Since protein kinase C (PKC) represents a downstream effector
of RhoA [30,33], we next investigated whether activation of PKC
isoforms was involved in uPA-dependent intracellular accumula-
tion of virions in U1 cell upon PMA stimulation. Isoform-selective
myristoilated pseudosubstrates peptides or control scrambled
peptides were applied to U1 cells, in the presence or absence of
PMA and uPA. As expected, blockade of Ca
++-dependent
PKCabc isoforms interfered with PMA-induced virus expression
in the absence of uPA, consistently with previous reports on the
role of PKC activation driving HIV expression [34]. Of interest,
the anti-HIV effect of uPA in PMA-stimulated U1 cells was
reversed exclusively by inhibition of PKCe, but not by PKCd
(Figure 1B). Ultrastructural analysis was performed on cells treated
with PKCe pseudosubstrate (Figure 1C and S1), showing that
inhibition of PKCe activation prevented both the formation of
cytoplasmic vesicles as well as virion accumulation into such
Figure 1. The anti-HIV activity of uPA is mediated by RhoA and PKCe, but not by PKCd. U1 cells were pre-incubated for 45–60 min at 37uC
with RhoA Trojan peptide (50 mM) (A) or myristoylated peptides specific for different PKC isoforms (50 mM) (B) and then stimulated with PMA (10 nM)
in the presence or absence of uPA (10 nM); culture supernatants were analyzed 48 h later for the levels of virus expression (mean6SD of 11
independent experiments). Nil represents the negative background RT activity of unstimulated U1 cells (typically, 120650 cpm/ml). P1; penetratin
was used at 50 mM as negative control of Trojan peptides. DMSO is the vehicle in which PKC pseudosubstrate is resuspended, and here used as
control. *p,0.05. (C) Cells were stimulated in the conditions specified above and analyzed by electron microscopy 48 h after stimulation; more
extensive selection of pictures is represented in the Supplementary Figures S1 and S2. iPKC; inhibitor of the specified PKC isoforms.
doi:10.1371/journal.pone.0023674.g001
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not show any effect in U1 cells stimulated with interleukin-6 (IL-6)
(Figure S2), a cytokine triggering HIV expression in U1 cells
without inducing cell adhesion and, therefore, insensitive to the
inhibitory effects of uPA [15].
All above inhibitors were used at concentrations that provide
the maximal biological effect in the absence of evident cellular
toxicity, as determined by cell proliferation (measured in terms of
overnight uptake of
3H-thymidine) and cell viability (by Trypan-
blue dye exclusion) [19] after 3 days of stimulation. A PKCf
pseudosubstrate was also tested, but resulted in either toxic effects
on the cells or in no effect on cell adhesion when used at non-toxic
concentrations (data not shown).
uPA-induced cell adhesion and cell polarization is
mediated by small GTPase RhoA, PKCd and PKCe
PMA stimulation of myelo-monocytic cell lines, including
promonocytic U937 and U1 cell lines, induce their activation
and differentiation along the macrophage lineage [26]. Such a
process is associated with the transition from cell proliferation in
suspension to a drastic decrease of the proliferative capacity and
acquisition of cell adhesion to the substrate. As we have previously
demonstrated in primary MDM [15], PMA-induced U1 cell
adhesion to the substrate was enhanced in the presence of uPA
(Figure 2A). Although both RhoA Trojan peptides failed to affect
PMA-induced cell adhesion; however, they fully prevented the
enhancement of adhesion to the substrate induced by uPA
(Figure 2A).
Next, we investigated whether activation of PKC isoforms was
involved in uPA-dependent increase of U1 cell adhesion following
PMA stimulation. In this regard, different studies have reported
that both PKCa and f regulate, concurrently with RhoA, b1 and
b2 integrin-dependent adhesion resulting in cell spreading and
lateral mobility of LFA-1, respectively [30,35]. As in the case of
HIV expression, blockade of Ca
++-dependentabc PKC isoforms
also interfered with PMA-induced cell adhesion (Figure 2B).
Furthermore, it has been reported that both uPA and ATF can
lead to formation of diacylglycerol (DAG) that, in turn, can
induce the activation of PKC d and e isoforms [36] associated
with promotion of cell adhesion and migration of human
epithelial cells [37,38]. Consistently, pharmacological targeting
of PKC d and e isoforms did not influence PMA-dependent cell
adhesion but fully prevented its enhancement induced by uPA
(Figure 2B).
Concomitantly with the enhancement of cell adhesion, uPA
inhibited homotypic cell aggregation, as reported [15]. PMA
induced formation of both adherent cells and of cell aggregates
that remained in suspension (Figure S2). Cell aggregation was
abolished and all cells were adherent to the substrate when co-
stimulated with PMA and uPA (Figure S2A). Trojan peptides
targeting the small GTPase RhoA did not modify PMA-induced
cell clustering but fully reversed the inhibitory effect of uPA (Figure
S3A). PMA-induced homotypic clustering of U1 cells was not
affected by the PKC pseudosubstrates tested (Figure S3A–B). In
addition, interference with PKC d or e, but not with the abc
isoforms, reversed the uPA-dependent inhibition of cell aggrega-
tion (Figure S3B).
In parallel to the induction of cell adhesion (and to the
prevention of cell aggregation) uPA induced a morphological
polarization of U1 cells, as previously observed in the case of
neutrophils [39], vascular smooth muscle and epithelial cells
stimulated by uPA or ATF [37]. Polarized cells were characterized
by the formation of classical uropods (Figure 3A and Figure S4)
that were only present in adherent cells. This change in cell shape
was still observed 48 h after stimulation. This finding is in
accordance to previous findings showing that binding of uPA to
uPAR on the surface of U937 cells is long-lasting, with ca. 80% of
input uPA bound to uPAR after 4 h [40]. Furthermore, uPA
proteolytic activity in the monocytic cell line THP-1 has been
shown to last for 40 h or longer [40]. Uropods formation was
indeed not observed when cells were cultivated in ULA plates
(data not shown), characterized by low binding of serum proteins
and lack of cell adhesion [15]. Unbiased quantification of the
number of polarized cells was performed on randomly selected
fields acquired by InCell analyzer (Figure 3A), with the cells being
analyzed for their width/length ratio by the InCell Investigator
software excluding from the analysis cells partially out of the field
(Figure S5). As observed by phase contrast microscopy (Figure S4),
the InCell Investigator software quantified that 4.7% and 15% of
the adherent U1 cells were indeed polarized after PMA or
PMA+uPA, respectively (Figure 3B). Furthermore, PMA-stimu-
lated U1 cells were characterized by the absence of uropods,
whereas co-stimulation with PMA and uPA induced a more
evident cell polarized characterized by a lower width/length ratios
and induced the formation of uropods (Figure 3B). Inhibition of
RhoA or PKCd or PKCe activities did not affect PMA-induced
cell polarization (data not shown) but abolished the enhancement
of cell polarization induced by uPA to values similar to those
observed in PMA-stimulated cells (Figure 3C). In contrast, RhoA
Trojan peptides did not show any effect in U1 cells stimulated with
interleukin-6 (data not shown), a cytokine triggering HIV
expression in U1 cells without inducing a macrophage-like
phenotype, therefore insensitive to the inhibitory effects of uPA
[15].
Table 1. PKCe and virion partitioning in stimulated U1 cells.
Stimuli p.m.-associated virions i.c. virions % virions pm/ic # vesicles per cell # cells with vesicles/total
PMA 74 0 100 1 1/10
PMA+iPKCe 199 3 98 2 2/10
PMA+uPA 58 79 42 .10 9/10
PMA+uPA+iPKCe 165 5 97 1.5 5/10
IL-6 46 0 100 0 0/10
IL-6+iPKCe 105 0 100 0 0/10
U1 cells were pretreated with PKCe pseudosubstrate and stimulated for 48 h with the indicated stimuli, and analyzed by transmission electron microscopy as previously
reported [14]. Unstimulated U1 cells did not show evidence of either virion production or cell vacuolization (not shown). p.m.: plasma membrane; i.c.: intracellular; iPKCe:
inhibitor of the isoform PKCe.
doi:10.1371/journal.pone.0023674.t001
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Since both cell adhesion and polarization are dependent on
cytoskeleton re-organization, intracellular distribution of globular
(G) and filamentous (F) actin was investigated. Two days after
PMA or PMA+uPA stimulation adherent U1 cells were stained
with probes specific for G and F actin, such as DNaseI and
phalloidin, respectively. In PMA-stimulated U1 cells G actin was
homogenously distributed, with F actin was localized below the
cellular membrane (Figure 4A) when U1 cells were stimulated by
PMA in the presence of uPA G actin was homogenously
distributed (Figure 4B), although levels of intensity were decreased
(Figure 4B and Figure S7A). However, uPA did not alter actin
expression [14] indicating that decreased levels of G actin intensity
are consequent of G to F switch, likely due to an increased volume
of uPA stimulated cells (Figure 3A and Figure S7A). Indeed,
distribution of F actin in PMA+uPA stimulated cells overlapped to
that observed in PMA stimulated cells, such as below the cellular
membrane, but also in tails present only in polarized cells
(Figure 4B).
uPA induces RhoA activation in PMA stimulated U1 cells
In order to assess the activated form of RhoA we measured the
GTP-bound form of RhoA by G-LISA. Unstimulated (Nil) and
PMA-stimulated cells showed equal levels of activated RhoA
(Figure 5A), confirming independent studies indicating that PMA
failed to activate RhoA in fibroblats [41]. In contrast, uPA induced
RhoA activation in both unstimulated and PMA-stimulated U1
cells (Figure 5A and 5B). RhoA activation reached a peak of
activation as soon as 5 min after uPA stimulation, returning to
basal levels after 60 min (Figure 5A and 5B). It should be
underscored that U1 cells at these early time points are still
completely in suspension, and that the same findings were
observed in ultra-low adhesion (Teflon-coated) plates (data not
shown).
The levels of RhoA activation were also analyzed after 24 and
48 h of culture. When both unstimulated and PMA-stimulated
cells were maintained in suspension in Teflon-coated plates the
levels of RhoA activation were constant over time (from 5 min to
48 h, Figure 5A and 5C, dashed lines), whereas it decreased by ,6
folds after 24–48 h in standard plates allowing cell adhesion
(Figure 5C and 5D), as described [32]. In contrast, uPA
stimulation caused an increased in RhoA activation exclusively
in cells that were allowed to adhere, but not in cells cultivated in
Teflon-coated plates, as observed after 24–48 h of culture
(Figure 5C and 5D). Thus, a second wave of RhoA activation,
likely consequent to integrin outside-in signaling, is generated and
maintained upon uPA-induced cell adhesion.
uPA induces activation of PKC e and d isoforms
We measured the activation of PKC isoforms in terms of their
translocation from the cytoplasm to the membrane [42] (Figure 6A)
as well as of the presence of phosphorylated isoforms (Figure 6B).
As expected, PMA induced the complete translocation of PKCa
from the cytosol to the plasma membrane as tested 10 min after
cell stimulation (Figure 6A), an event that was unaffected by uPA
(data not shown). PKCe was detected exclusively in the cytosolic
fraction of unstimulated U1 cells while PMA poorly induced its
translocation to the plasma membrane (Figure 6A). Stimulation of
U1 cells with uPA alone induced a time-dependent PKCe
translocation to the membrane (Figure 6A). When cells were co-
stimulated with PMA and uPA, however, a synergistic effect was
observed on the translocation of this PKC isoform from the cytosol
to the membrane that was already maximal 10 min after
stimulation and remained elevated for at least an additional
50 min.
In comparison to PKCe PKCd showed faster kinetics of
translocation from the cytosol to the plasma membrane that was
already maximal 10 min after stimulation with uPA in the absence
of PMA (Figure 6A). Like PKCe, also for PKCd the strongest
Figure 2. uPA induces adhesion of PMA-differentiated U1 cells via activation of small GTPase RhoA, PKCd and PKCe. U1 cells were
pre-incubated for 45–60 min at 37uC with RhoA Trojan peptide (A) or myristoylated peptides specific for different PKC isoforms (B) and then
stimulated with PMA in the presence or absence of uPA; cells were analyzed 48 h later for their capacity to adhere to the plastic substrate. uPA
increased the adhesion of PMA-stimulated U1 cells and this effect was reversed by inhibition of either RhoA or different PKC isoforms. Results are
shown as mean 6 SD of 11 independent experiments. Nil indicates unstimulated U1 cells, showing a mean net absorbance value (subtracted of the
background value of an empty well) of 0.0760.012. *p,0.05.
doi:10.1371/journal.pone.0023674.g002
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with PMA and uPA. This pattern is likely explained by the
observation that PMA has been shown to enhance uPAR affinity
for uPA, either directly or indirectly affected by PKC [43].
Since membrane fractionation does not allow isolation of
plasma membrane from total membranes, a second method for
analyzing PKC activation was used, and intracellular levels of
activated isoforms was performed by cytofluorimetric analysis. U1
cells stained negative for activated PKCe, whereas 30 min of
stimulation with either PMA alone or uPA poorly induced its
phosphorylation. However, PMA+uPA stimulation induced phos-
phorylation of PKCe in most cells (Figure 6B). Related to activated
PKCd PMA did not induce appreciable activation, whereas cell
stimulation with either uPA alone or in the presence of PMA
increased the number of cells positive for phosphorylated PKCd
(Figure 6B).
Cytochalasin D (CytD) mimics the anti-HIV activities of
uPA in PMA-stimulated U1 cells
We have previously reported that both b1 and b2 integrin chains
mediate the antiviral effect of uPA in PMA-stimulated U1 cells as
well as that integrin activation in the absence of uPA led to a
similar effect [19]. Since integrin function is linked to the
cytoskeleton activity we investigated the potential role of
cytoskeletal elements in HIV expression and uPA-dependent
effects. Therefore, U1 cells were stimulated in the presence or
absence of CytD, a cell-permeable fungal toxin that prevents F
actin polymerization and induces RhoA activation [32].
CytD did not influence the basal undetectable levels of virus
expression in unstimulated U1 cells (Figure 7A), but it inhibited
HIV release in PMA-stimulated cells to an extent comparable to
that induced by uPA (Figure 7A). We next freeze-fractured CytD-
treated cells and observed an increase in RT activity reaching
levels to those of control PMA-stimulated cells, similar to what
observed with uPA (Figure 7B), suggesting that the anti-HIV
activity of CytD, as described for uPA [14], likely results in the
intracellular budding and accumulation of virions; indeed,
independent studies reported that CytD did not inhibit HIV
proteins expression and maturation but HIV virion release in
monocytic and T cell lines (U937 and Jurkat, respectively) [44,45].
Consistently with independent findings [32,46], we observed
activated RhoA after 30 min of CytD incubation, an effect that
lasted for at least 2 h, independently of the presence of PMA
(Figure 7C). Similarly to what observed in uPA-stimulated cells
(Figure 5A) the levels of RhoA activation were enhanced of about
50% (Figure 7D). Furthermore, CytD induced adhesion of
unstimulated U1 cells, as reported for other cell types [47], and
this effect was additive in the presence of PMA (Figure 7E).
CytD induced polarization of U1 cells, as reported on other cell
types [47,48], and also this effect was dependent upon PKCe
activation (Figure 8A). CytD induced cell polarization as soon as
after 15 min of stimulation and independently of cell adhesion.
Moreover, like uPA, CytD also prevented the formation of cell
aggregates in PMA-stimulated cells after 48 h of stimulation,
another effect that was prevented by inhibition of PKCe activation
(Figure 8A). We have also analyzed distribution of G and F actin in
CytD adherent cells. As previously reported in fibroblasts [49], F
actin resulted to be localized in focal aggregates (Figure 8B, middle
panels), excluded from tails present in polarized cells. G actin was
broadly distributed and also present in tail of polarized cells
(Figure 8B, middle panels). PMA+CytD stimulated U1 cells were
characterized by a morphology similar to that observed with CytD
alone, although increased levels of intensity of F actin were
noticed, probably due to the addictive adhesion effect induced by
PMA and CytD (Figure 8B, bottom panels and Figure S6B).
As in U1 cells stimulated with PMA+uPA, CytD-induced cell
adhesion was dependent on RhoA and PKCe activation
(Figure 7E). Noteworthy, however, unlike uPA, the anti-HIV
Figure 3. uPA induces polarization of PMA-differentiated U1
cells. U1 cells were loaded with cell tracker (red color) and then
stimulated with PMA in the presence or absence of uPA. Adherent cells
were stained 2 days later for F-actin (phalloidin-FITC, green color) and
nuclei(bluecolor). Atotalof 1,142and2,245 adherentcells werecounted
after stimulation with either PMA alone or in the presence of uPA,
respectively. (A) uPA induces polarization of U1 cells with formation of
uropods, not observed in control cells stimulated only with PMA. (B)
Quantification and distribution of polarized cells, as defined by form
factor ,0.8. (C) Inhibition of anti-RhoA or PKC d and e isoforms reverted
uPA-induced cell polarization: this analysis is based on the distribution of
the cell tracker (right panels, red light) since staining of F-actin (left
panels, green light) revealed the presence of filopodia, cell surface
projections highly enriched in F-actin required for the formation of focal
adhesion sites [73] that may produce false-positive results.
doi:10.1371/journal.pone.0023674.g003
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PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23674Figure 4. Different actin distribution in uPA polarized cells. U1 cells were stimulated with PMA in the presence or absence of uPA and actin
distribution in adherent cellswas visualized by confocal microscopy after 48 h of culture. Hoechst-33342, DNase I (Alexa Fluor488, green) andphalloidin
(AlexaFluor633,red) wereusedtodiscriminatenuclei,globular(Gactin)andfilamentous(Factin)isoforms,respectively.Imageswereacquiredwith636
magnification by Leica TCS SP2 confocal microscope (Figure S6) and electronically zoomed 3 times. Image J software was used to perform montage of
the three colors. Yellow arrows indicate polarized cells. One experiment out of three independently performed with similar results is shown.
doi:10.1371/journal.pone.0023674.g004
Figure 5. uPA induces two waves of RhoA activation in PMA-activated U1 cells. Quick RhoA activation in U1 cells upon uPA stimulation:
absorbance indicating RhoA activation was measured by the G-LISA kit assay and was normalized per mgo fp r o t e i n( A) and results of 3 independent
experiments reported ad fold induction (mean 6 STD) vs. unstimulated cells (B). Delayed uPA-induced activation of RhoA is adhesion-dependent: RhoA
activation was measured in PMA or PMA+uPA stimulated U1 cultivated in culture plates (adherent cells) or in Teflon-coated plates not allowing adhesion
(suspended cells) (C),andresultsof3independentexperimentsreportedadfoldinduction(mean6STD)vs.PMAstimulatedcells.Thedottedlineinpanels
A and C indicate the levels of RhoA activation observed in unstimulated cells (panel A) and in cells maintained in suspension in ULA plates after stimulation
for 24–48 h with PMA (C). Calpeptin (2 U/ml for 15 min) was used as positive control and induced 260.1 fold of RhoA activation vs. Nil (not shown).
doi:10.1371/journal.pone.0023674.g005
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superimposable results were obtained in Teflon-coated plates
preventing cell adhesion (Figure 7F).
Discussion
In the present study, we have investigated the signaling
determinants involved in uPA-dependent inhibition of HIV-1
expression in a well defined model of macrophage infection such
as chronically infected promonocytic U1 cells activated and
differentiated by PMA. Indeed, several features typical of primary
macrophage infection are observed in PMA-stimulated U1 cells,
including the shift from growth in cell suspension to firm adhesion
to the substrate coinciding with growth arrest [15] and the
expression of the CD11b integrin chain [19], as also reported in
the U1 uninfected parental cell line U937 [43]. Morphologically,
PMA-differentiated U1 cells acquire a macrophage-like phenotype
characterized by a ruffled plasma membrane and a vacuolarized
cytoplasm where HIV frequently buds into and accumulate,
particularly when IFN-c or uPA are applied together with PMA
[14,23]. Finally, PMA-stimulated U1 cells resembles primary
human MDM in terms of secretion of uPA, soluble uPAR (suPAR)
and suPAR/uPA ratio [19].
Both the small GTPase RhoA and DAG-activable PKC
isoforms d and e were activated by uPA. Along with increased
U1 cell adhesion and inhibition of homotypic cell clustering, uPA
induced polarization of PMA-stimulated U1 cells and RhoA
activation. However, only RhoA and PKCe were linked to the
intracellular accumulation of HIV virions, while uPA-dependent
increased cell polarization and adhesion were dependent on
RhoA, PKCd and PKCe. CytD recapitulated through different
dynamics all the essential features of uPA-dependent modulation,
such as U1 cell adhesion, polarization and prevention of HIV
virions release.
The uPA/uPAR complex has been involved in multiple
biological processes and its dysregulation has been linked to
important pathological conditions, including the formation of
cancer metastasis and HIV/AIDS disease progression [3]. uPA
activities can be subdivided in those processes consequent to its
proteolytic component from those occurring after signaling
mediated by uPAR association with a transducing receptor. The
modulatory effects here investigated are strictly associated with this
‘‘second life’’ of uPA, such as cell adhesion, polarization and anti-
HIV activity [14,20]. uPA-induced chemotaxis of human vascular
smooth muscle cells was reported to be mediated by activation of
small GTPase RhoA and downstream phosphorylation of myosin
light chain [50]. In this regard, the small GTPase RhoA has been
previously implicated in chemoattractant-induced b1 [51] and b2
integrin mediated leukocyte adhesion, and, particularly, for aLb2
(LFA-1), in the regulation of heterodimer affinity increase and
lateral mobility [30,52], as well as in the enhancement of
monocyte and promonocytic U937 cell adhesion to the substrate
[53,54] and very recently of neutrophil adhesion on fibrinogen
[55].
Consistently, our previous [15] and current findings link them
to the anti-HIV effect of uPA in various models of macrophage
infection (including primary MDM and PMA-differentiated U1
cells) to an increased cell adhesion and to the activation of RhoA.
Of interest is the fact that an inhibitory effect of transfected RhoA
on HIV gene transcription and replication was demonstrated to
Figure 6. uPA induces activation of PKCd and e in PMA-stimulated U1 cells. PKC activation was measured by two independent assays, such
as cytosol-membrane translocation of PKC and measurement of PKC isoforms phosphorylation. Cells were left either unstimulated or were incubated
with PMA in the presence or absence of uPA. (A) Membrane and cytosolic fractions of U1 cells were analyzed for the presence of PKC isoforms at the
indicated time points; membrane and cytosolic extracts were run independently but in a single gel per fraction. (B) Cells were analyzed by
cytofluorimetric means for the presence of phosphorylated PKCe and PCKd 30 min after stimulation (numbers in parentheses represent the % of
positive cells and geometric means of fluorescence, respectively). The results shown in A and B were obtained from a single experiment
representative of 5 independently performed.
doi:10.1371/journal.pone.0023674.g006
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adherent Jurkat T lymphocytic cells [56]. In contrast, a positive
role of RhoA activation has been described in dendritic cells
following DC-SIGN activation and formation of an immunovir-
ological synapse with T cells [57]. However, these two seemingly
opposite effects may in fact represent two consequence of the same
Figure 7. CytD inhibits late phase of HIV expression via activation of small GTPase RhoA and PKCe. (A) U1 cells were resuspended in
culture medium supplemented of either CytD (10 mM) or 10 nM uPA and then left unstimulated or stimulated with PMA. Kinetics (left panel) and % of
inhibition after 48 h of stimulation (right panel) are shown from 1 experiment representative of 4. (B) RT activity was measured after 72 h of
stimulation in the supernatant of cells before and after being subjected to cycles of freezing and thawing. The results from 1 experiment out of 2
independently performed are shown. (C) RhoA activation in U1 cells upon CytD stimulation: absorbance indicating RhoA activation was measured by
the G-LISA kit assay and was normalized per mg of protein. (D) Results of 3 independent experiments reported ad fold induction (mean 6 STD) vs.
unstimulated cells. (E) U1 cell adhesion was measured after 48 h of stimulation; the results are represented as fold induction vs. unstimulated U1 cells
(Nil; with net OD values, subtracted of background, ranging between 0.05–0.06). (F) The RT activity was measured in the culture supernatants after
48 h of stimulation; the results are represented as fold of induction vs. PMA-stimulated U1 cells (with values ranging between 2,500–3,000 cpm/mli n
standard plates (TC, tissue culture) allowing cell adhesion and 8,000–10,000 cpm/ml in ultra-low adhesion (ULA) plates, as reported [15]. Panels (E) and
(F) show the average6SD of 4 independent experiments; control peptides, such as P1 and scrambled PKC pseudosubstrate produced results
superimposable to those of DMSO. *p,0.05.
doi:10.1371/journal.pone.0023674.g007
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lular vesicles that could represent an inhibitory outcome for free
virion release, but facilitate cell-cell virion transmission.
Downstream to RhoA [30,33], activation of PKC is crucial for
modulation of several cellular processes. In this regard, activation
of PKC isoforms influences the morphology of the F-actin
cytoskeleton and thereby regulates processes that are affected by
remodeling of the microfilaments [42]. Integrins are crucial
mediators both upstream and downstream of PKC in inducing
morphological changes [42]. In addition, HIV virions and
cytoskeleton elements strongly interact each other after the entry
step or in order to bud from the infected cell as also evidenced by
the incorporation of actin and actin-binding molecules into virions
[58,59]. Thus, PKC activation may lead to the regulation of virus
Figure 8. CytD induces U1 cell polarization and modification of actin distribution. U1 cells were stimulated with CytD in the presence or
absence of PMA. (A) U1 cells were pre-incubated for 45–60 min at 37uC with the PKCe inhibitor and then stimulated with either CytD or CytD+PMA;
cell polarization was visualized 15 min and 48 h after stimulation. Phase contrast pictures of cells were shot at 206 magnification; arrowheads
indicate polarized structures. (B) G and F actin distribution in adherent U1 cells; upper panels show the effect of PMA stimulation, middle panels
those of CytD stimulation and bottom panels of PMA+CytD co-stimulation. Staining of G and F actin, image acquisition and montage were performed
as describe in the Figure 4 legend. Yellow arrows indicate polarized cells. One out of 3 independent experiments performed with similar results is
shown.
doi:10.1371/journal.pone.0023674.g008
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or by phosphorylating viral proteins [62], or indirectly via
induction of cytoskeleton rearrangement. In particular, PKCe
has been shown to phosphorylate vimentin (VM) [63] a
cytoskeleton protein important for the cytoplasmic localization of
the viral accessory protein Vif [64], therefore affecting virion
infectivity [65]. VM activation can trigger the association of
vesicle-bearing b1 integrins to intermediate filaments, thus
allowing their movement towards the plasma membrane [63].
uPA-mediated activation of PKCe might regulate VM activity by
altering its interactions with Vif and the viral protease [66]
ultimately resulting in the accumulation of virions in intracellular
vacuolar compartments. In this regard, blocking events down-
stream to PKCe erased the ability of uPA to induce intracellular
vacuolization, a marker of functionally mature phagocytes [67].
Overall, these findings suggest that uPA-induced activation of
Figure 9. RhoA and PKCe activation leads to accumulation of HIV virions in cytoplasmic vacuolar compartments. (A) CytD mediated
accumulation of virions is reversed by blocking RhoA and PKCe independently of cell adhesion. The same enzymes also modulate cytoskeletal
rearrangement, as evident by cell polarization shown in Figure 8 and promote cell adhesion and inhibition of cell clustering [74]. (B) Binding of the
signaling-competent portion of uPA (ATF) to uPAR recruits VN [15,75] leading to dimerization of the complex likely occurring in lipid rafts [76] (white
box inside the dashed box representing cell membrane, whereas stars represent GPI-anchor associated to uPAR) (step 1), independently of integrin
activation [77], followed by early activation of RhoA and then PKCe (step 2). Cytoskeleton is rearranged (step 3) leading to two events, such as i)
reinforcement of cell adhesion (step 4a) [32,78] generating a second wave of RhoA activation (step 5), and ii) activation/clustering of b1 and b2
integrin chains (step 4b) [19] therefore generating a signaling cascade leading to the intracellular accumulation of virions in intracellular vesicles
(step 6). Full arrows represent our experimental findings, whereas dashed arrows are hypothetical.
doi:10.1371/journal.pone.0023674.g009
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(i.e., needed for recycling of membrane receptors during
chemotaxis), a system reported to be exploited by HIV in infected
macrophages [68].
In order to better define the role of cytoskeleton in uPA-
mediated activities, we also studied the effect of Cytochalasin D, a
cell-permeable compound that does not require interaction with
any membrane receptor to mediate both RhoA activation and
cytoskeleton remodeling. CytD has been reported that it binds to
the barber end of G actin thus preventing the following
polymerization to F actin and leading to the accumulation of G
actin. Moreover, it has been reported that F actin sequesters Rho
guanine-nucleotide exchange factor, thus abrogating RhoA
activation [69]; indeed, also microtubule disruption with either
nocodazole or colchicines has been reported to increase global
RhoA activity in neutrophils [70]. Consistently with this model we
observed increased levels of activated RhoA upon 30 min of
incubation, as reported independently [32,46], after cytoskeletal
rearrangement, an event that occurred as soon as after 15 min of
treatment. Indeed, inhibition of RhoA reversed CytD-induced cell
adhesion and inhibition of HIV release. Nonetheless, cell
adhesion, polarization and inhibition of HIV release induced by
CytD were also mediated by PKCe, an enzymatic activity
reported to be downstream of RhoA-mediated signaling. Thus, a
potential model of uPA/uPAR interaction may include the
generation of an intracellular signal of reorganization of
cytoskeleton components similar to that induced by CytD
(Figure 9A) that inhibits virus replication at the level of virion
assembly and release [45].
A potential working model connecting the multiple events induced
by the uPA/uPAR system is shown in Figure 9B. According to this
model, uPA/uPAR/VN complex likely triggers an outside-in
signaling cascade facilitating cell adhesion and polarization of
adherent cells. Since cell polarization occurred exclusively in
adherent cells, but not in cells maintained in suspension in ULA
plates, the intracellular signaling triggered by uPA, involving the
activation of RhoA and PKC d and e, is crucial for the acquisition
of cell polarity (i.e. formation of the uropods and, eventually,
pseudopods), as previously discussed for epithelial cells [37], needed
formigrationonsubstrate.Conversely,theVN/uPA/uPARcomplex
might generate an ‘‘inside-out’’ signaling by perturbing the cytos-
keleton organization triggering integrin activation that, in turn, may
trigger an ‘‘outside-in’’ signaling pathway leading to cell polarization,
as reported for CXCL12-dependent integrin activation, reported to
induce cell adhesion and migration via activation of RhoA followed
by activation of the integrin LFA-1 [41,71,72].
Thus, the uPA/uPAR/VN system favors macrophage adhesion
and accumulation of virions in intracellular vesicles [68],
highlighting a potential mechanism for the establishment and
maintenance of this intra-cytoplasmic reservoir of preformed
virions. Such a feature of virion morphogenesis has generated the
model of macrophages as ‘‘Trojan horses’’ of infection, hiding
infectious virions from the recognition of immune effectors such as
neutralizing antibodies [68]. Finally, our results also extend uPA/
uPAR-related findings to a broader model that involves pathways
controlling cytoskeleton remodeling and activation of RhoA and
PKCe as mediators of intracellular accumulation of HIV virions in
vesicles as well as their release from infected macrophages.
The possibility of interfering with either the uPA/uPAR/VN
system, RhoA or PKCe might therefore suggest novel targets to
eliminate such an intracellular virion reservoir by facilitating virion
release from tissue macrophages, including uPAR
+/CD68
+ mac-
rophages accumulating virions described in the CNS of HIV
+
individuals [13].
Supporting Information
Figure S1 UPA-mediated vesicles formation and accu-
mulation of virions into vesicles are dependent of PKCe.
U1 cells were preincubated for 45–60 min at 37uC with
myristoilated peptides specific for PKCe isoform and were then
stimulated with PMA in the presence or absence of uPA for 48–
72 h, then prepared for and analyzed by EM as described in
material and methods. Four representative images are shown for
each treatment (the third picture of the first panel shows
enlargement of virion). Scale bar is reported at the bottom of
each picture.
(TIF)
Figure S2 PKCe does not influence IL-6 induced HIV
expression. U1 cells were preincubated for 45–60 min at 37uC
with myristoilated peptides specific for PKCe isoform and were
then stimulated IL-6, then prepared for and analyzed by EM as
described in material and methods. Four representative images are
shown for each treatment (the third picture of the first panel shows
enlargement of virion). Scale bar is reported at the bottom of each
picture. (B) Culture supernatants were analyzed 48 h later for the
levels of virus expression (mean6SD of duplicate cultures).
(TIF)
Figure S3 PMA-induced cell aggregation is prevented by
uPA and reversed by blocking small GTPase RhoA and
PKCd or PKCeactivation. (A) U1 cells were preincubated for
45–60 min at 37uC with either RhoA23 or RhoA92 Trojan
peptides and were then stimulated with PMA in the presence or
absence of uPA. Cells were left in their original culture well (not
washed to allow persistence of both adherent and suspended cells).
Pictures were shot 48 h later for visualizing homotypic cellular
clustering (objective magnification 406). The results of one
experiments representative of 4 independently performed are
shown. P1; penetratin was used as negative control of Trojan
peptides. (B) U1 cells were pre-incubated for 45–60 min at 37uC
with myristoylated peptides specific for different PKC isoforms
and were then stimulated with PMA in the presence or absence of
uPA. Cells were left in the original culture well and pictured 48 h
later for homotypic cellular clustering (objective magnification
406). The results of one experiments representative of 4
independently performed are shown. ‘‘Scramble’’ indicates an
irrelevant myristoilated peptide used as negative control.
(TIF)
Figure S4 uPA induced cell polarization is reversed by
blocking RhoA and PKCe.Aand B. Cells were stimulated as
described in Figure 1 and then washed to remove non-adherent
cells. Arrowheads indicated polarized structures. Pictures (magni-
fication: 406) from 1 experiment representative of 11 indepen-
dently performed are shown.
(TIF)
Figure S5 Analysis of cell morphology and associated
cell width/length ratio. (A) U1 cells were loaded with cell
tracker and then stimulated with PMA+uPA. Adherent cells were
stained 2 days later for visualizing their nuclei. Representative cells
(objective magnification of 406) and their form factor are shown.
Red dotted shapes are automatically generated by the IN Cell
Investigator Software, based of the distribution of cell tracker, and
used to calculate the form factor. (B) A total of 1142 and 2245
adherent cells were counted in PMA and PMA+uPA stimulated
cells. Unlike what shown in Figure 4B, width/length ratio axis also
includes non polarized cells, meaning ratios between 0.8 and 1.
Panels C and D represent the absolute percentage of polarized
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between experiments, respectively.
(TIF)
Figure S6 Actin distribution in U1 stimulated cells. U1
cells were stimulated with PMA in the presence or absence of
uPA/CytD and actin distribution in adherent cells was visualized
after 48 h of culture by confocal microscopy. Hoechst-33342,
DNase I (Alexa Fluor 488, green) and phalloidin (Alexa Fluor 633,
red) were used to discriminate nuclei, globular (G actin) and
filamentous (F actin) isoforms, respectively. Upper panels show
PMA stimulated U1 cells in abscence or presence of uPA; bottom
panels show CytD stimulated U1 cells in absence or presence of
PMA. Image J software was used to perform montage of the three
colors. One experiment out of three with similar results is shown.
Images were acquired with 636magnification by Leica TCS SP2
confocal microscope.
(TIF)
Figure S7 Different modulation of G and F actin
distribution by uPA and CytD in stimulated U1 cells.
U1 cells were stimulated and treated as described in the legend of
figure S5. Upper panels show G-actin distribution in U1 cells
cultivated with all different stimuli; bottom panels show F-actin in
the same stimulated U1 cells. Images were acquired with 636
magnification by Leica TCS SP2 confocal microscope and
electronically zoomed 3 times.
(TIF)
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